source
- Melanoma vaccine shows 42% risk reduction at ESMO 2026, but shares tumble on early data releaseModerna and Merck presented Phase 3 results for their melanoma vaccine intismeran autogene at the European Society for Medical Oncology meeting. The trial reported a 42% reduction in the relative r…
- Boehringer Ingelheim and Microsoft launch AI partnership to develop digital patient twins for clinical trialsBoehringer Ingelheim and Microsoft announced a collaboration to investigate AI driven digital patient twins that model individual patients for clinical trial design. The work will explore disease…